Dasatinib-induced chylothorax: a clinical laboratory’s perspective

Other authors

Institut Català de la Salut

[Martínez RJG] Clinical Analysis Department, Marqués de Valdecilla University Hospital, Santander, Spain. Evidence-Based Laboratory Medicine Commission, Spanish Society of Laboratory Medicine (SEQCML), Barcelona, Spain. [Gea CS, Martin-Riera V, Ruiz ARG, Barzanti RP, Ferrer-Costa R, Ramirez-Serra C] Grup de Recerca de Bioquímica Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Bioquímica Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-05-10T06:47:20Z

2023-05-10T06:47:20Z

2023-04-18



Abstract

Dasatinib; Pleural effusion chylothorax


Dasatinib; Derrame pleural quilotórax


Dasatinib; Vessament pleural quilotòrax


Dasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a secondary effect of dasatinib occurring especially in long-term treated patients, although its pathophysiology is not yet fully understood. Laboratory analysis of the pleural effusion is crucial for chylothorax diagnosis. We report a case of a 53-year-old male patient presenting a chylothorax after 14 years of dasatinib therapy where the clinical laboratory was key in the diagnosis.

Document Type

Article


Published version

Language

English

Publisher

International Federation of Clinical Chemistry and Laboratory Medicine

Related items

EJIFCC;34(1)

https://cms.ifcc.org/wp-content/uploads/2023/04/eJIFCC2023Vol34No1pp076-080.pdf

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial 4.0 International

http://creativecommons.org/licenses/by-nc/4.0/

This item appears in the following Collection(s)